^
Association details:
Biomarker:NPM1 mutation
Cancer:Acute Myelogenous Leukemia
Regimen:FLAI (cytarabine + fludarabine IV + idarubicin hydrochloride)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden

Published date:
12/24/2020
Excerpt:
Here, we investigated the efficacy of a fludarabine, high-dose cytarabine and idarubicin induction (FLAI) in 149 consecutive fit AML patients (median age 52) carrying the NPM1... Our data indicate that FLAI exerts a strong anti-leukemic effect in younger AML patients with NPM1mut...
DOI:
10.3390/cancers13010034